Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pfizer-BioNTech COVID-19 vaccine booster in SLE and RA patients previously vaccinated with inactivated or viral-vector COVID-19 vaccines
TCTR20211220004Phase 3Active, not recruiting
- Sponsor
- Ratchadaphiseksomphot Endowment Fund
- Start
- Oct 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tozinameran in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), coronavirus disease 2019 (COVID-19), sponsored by Ratchadaphiseksomphot Endowment Fund. Started Oct 2021; status: active, not recruiting.
02
Drugs
tozinameran
03
Conditions
systemic lupus erythematosus (SLE)rheumatoid arthritis (RA)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20211220004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20211220004.